JP2018515493A5 - - Google Patents

Download PDF

Info

Publication number
JP2018515493A5
JP2018515493A5 JP2017557901A JP2017557901A JP2018515493A5 JP 2018515493 A5 JP2018515493 A5 JP 2018515493A5 JP 2017557901 A JP2017557901 A JP 2017557901A JP 2017557901 A JP2017557901 A JP 2017557901A JP 2018515493 A5 JP2018515493 A5 JP 2018515493A5
Authority
JP
Japan
Prior art keywords
composition
amino acid
acid sequence
infusion
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017557901A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515493A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/060360 external-priority patent/WO2016177913A1/en
Publication of JP2018515493A publication Critical patent/JP2018515493A/ja
Publication of JP2018515493A5 publication Critical patent/JP2018515493A5/ja
Priority to JP2021036849A priority Critical patent/JP2021100943A/ja
Priority to JP2023078474A priority patent/JP7685008B2/ja
Priority to JP2025082282A priority patent/JP2025118898A/ja
Pending legal-status Critical Current

Links

JP2017557901A 2015-05-07 2016-05-09 Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物 Pending JP2018515493A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021036849A JP2021100943A (ja) 2015-05-07 2021-03-09 Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物
JP2023078474A JP7685008B2 (ja) 2015-05-07 2023-05-11 Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物
JP2025082282A JP2025118898A (ja) 2015-05-07 2025-05-16 Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562158153P 2015-05-07 2015-05-07
US62/158,153 2015-05-07
US201562221393P 2015-09-21 2015-09-21
US62/221,393 2015-09-21
US201562246949P 2015-10-27 2015-10-27
US62/246,949 2015-10-27
PCT/EP2016/060360 WO2016177913A1 (en) 2015-05-07 2016-05-09 Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021036849A Division JP2021100943A (ja) 2015-05-07 2021-03-09 Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物

Publications (2)

Publication Number Publication Date
JP2018515493A JP2018515493A (ja) 2018-06-14
JP2018515493A5 true JP2018515493A5 (https=) 2019-06-13

Family

ID=56008603

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017557901A Pending JP2018515493A (ja) 2015-05-07 2016-05-09 Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物
JP2021036849A Pending JP2021100943A (ja) 2015-05-07 2021-03-09 Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物
JP2023078474A Active JP7685008B2 (ja) 2015-05-07 2023-05-11 Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物
JP2025082282A Pending JP2025118898A (ja) 2015-05-07 2025-05-16 Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021036849A Pending JP2021100943A (ja) 2015-05-07 2021-03-09 Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物
JP2023078474A Active JP7685008B2 (ja) 2015-05-07 2023-05-11 Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物
JP2025082282A Pending JP2025118898A (ja) 2015-05-07 2025-05-16 Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物

Country Status (13)

Country Link
US (2) US11034760B2 (https=)
EP (1) EP3292147A1 (https=)
JP (4) JP2018515493A (https=)
KR (1) KR20180004254A (https=)
CN (2) CN121588213A (https=)
AU (1) AU2016257023B2 (https=)
BR (1) BR112017023867A2 (https=)
CA (1) CA2985001A1 (https=)
EA (1) EA037532B1 (https=)
IL (3) IL302519A (https=)
MX (3) MX2017014294A (https=)
SG (1) SG10202108996PA (https=)
WO (1) WO2016177913A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121588213A (zh) 2015-05-07 2026-03-03 瑞典孤儿比奥维特鲁姆股份公司 用于诊断和治疗cxcl9和其它生物标志物水平升高的患者的病症
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
WO2016200627A1 (en) 2015-06-09 2016-12-15 Children's Hospital Medical Center Dosing algorithm for complement inhibitor
EP3528845A2 (en) * 2016-10-24 2019-08-28 Novimmune S.A. Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
CN109116037B (zh) * 2017-11-27 2022-02-15 首都医科大学附属北京友谊医院 细胞因子在指示噬血细胞综合征相关疾病的治疗进展中的应用
EP3717004A4 (en) * 2017-12-01 2021-12-01 Children's Hospital Medical Center COMPOSITIONS FOR BLOCKING INTERERONS AND THEIR METHODS OF USE
EP3762416A4 (en) * 2018-03-09 2021-12-08 Children's Hospital Medical Center COMPOSITIONS AND METHODS OF TREATMENT OF MACROPHAGE ACTIVATION SYNDROME
CN113045655A (zh) * 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 抗ox40抗体及其用途
WO2021185832A1 (en) 2020-03-16 2021-09-23 Swedish Orphan Biovitrum Ag New therapeutic treatment
JP7396213B2 (ja) * 2020-06-22 2023-12-12 Tdk株式会社 データ解析システム、データ解析方法及びデータ解析プログラム
CN115812671B (zh) * 2022-11-17 2024-07-19 青岛大学 帕金森病动物模型的建立方法及其应用
WO2024254401A1 (en) 2023-06-09 2024-12-12 Children's Hospital Medical Center Treatment of stem cell graft failure

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US5096705A (en) 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4599306A (en) 1983-04-15 1986-07-08 Amgen Monoclonal antibodies which specifically bind to human immune interferon
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP3887011B2 (ja) 1992-12-29 2007-02-28 ジェネンテク，インコーポレイテッド ＩＦＮ−γインヒビターによる炎症性腸疾患の処置
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US20030059428A1 (en) 1993-02-26 2003-03-27 Boris Skurkovich Treatment of autoimmune diseases
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
US6861056B2 (en) 2001-06-05 2005-03-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US6534059B2 (en) 2001-06-05 2003-03-18 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
JP5290489B2 (ja) 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
EP1506002A4 (en) 2002-05-17 2006-06-07 Protein Design Labs TREATMENT OF CROHN'S DISEASE OR PSORIASIS FROM ANTI-INTERFERON GAMMA ANTIBODIES
US20040052791A1 (en) 2002-05-22 2004-03-18 Rolf Ehrhardt Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies
AU2003285874A1 (en) 2002-10-16 2004-05-04 Amgen Inc. HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
GB0314461D0 (en) 2003-06-20 2003-07-23 Isis Innovation Suppression of transplant rejection
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
MX2007008719A (es) * 2005-01-27 2007-09-11 Novimmune Sa Anticuerpos anti-interferon gamma y metodos de uso de los mismos.
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US7504106B2 (en) 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
GB0607943D0 (en) 2006-04-21 2006-05-31 Novartis Ag Biomarkers for chronic transplant dysfunction
CA2682292A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
KR101247418B1 (ko) 2007-12-21 2013-03-25 에프. 호프만-라 로슈 아게 항체 제형
WO2010042705A1 (en) 2008-10-09 2010-04-15 Medimmune, Llc Antibody formulation
MX2011009312A (es) 2009-03-06 2012-02-29 Medimmune Llc Formulaciones de anticuerpos humanizados anti-cd19.
MX2012007676A (es) * 2009-12-29 2012-08-03 Hoffmann La Roche Nueva formulacion de anticuerpo.
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
ES2676205T3 (es) * 2011-03-31 2018-07-17 Merck Sharp & Dohme Corp. Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados
US20130142809A1 (en) * 2011-11-23 2013-06-06 Andrew A. Welcher METHODS OF TREATMENT USING AN IFN gamma INHIBITOR
JPWO2015190378A1 (ja) 2014-06-10 2017-04-20 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 安定なアダリムマブ水性製剤
EP3237000A1 (en) * 2014-12-23 2017-11-01 Pfizer Inc Stable aqueous antibody formulation for anti tnf alpha antibodies
CN121588213A (zh) 2015-05-07 2026-03-03 瑞典孤儿比奥维特鲁姆股份公司 用于诊断和治疗cxcl9和其它生物标志物水平升高的患者的病症
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
EP3528845A2 (en) 2016-10-24 2019-08-28 Novimmune S.A. Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications

Similar Documents

Publication Publication Date Title
JP2018515493A5 (https=)
JP6554155B2 (ja) Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
EP2750709B1 (en) Cachexia treatment
KR102104296B1 (ko) 종양성 질병들에 대한 치료
JP2014114288A5 (https=)
JP7288927B2 (ja) 乾癬性関節炎患者における構造的損傷の進行を阻害するためのｉｌ－１７アンタゴニストの使用
JP7145162B2 (ja) 化膿性汗腺炎の処置
CN104800844A (zh) 使用il-17拮抗剂治疗类风湿性关节炎的方法
KR20230155586A (ko) 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법
AU2014314053B2 (en) Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
ES2992409T3 (es) Métodos de tratamiento de la psoriasis en placas de nueva aparición usando antagonistas de IL-17
KR20200088857A (ko) Il-17 길항제에 의한 화농성 한선염의 치료
AU2016250388A1 (en) Treatment for rheumatoid arthritis
RU2014117510A (ru) Лечение ревматоидного артрита
JP2022523530A (ja) 化膿性汗腺炎の治療のための抗ＩＬ－α抗体
JP2019532970A5 (https=)
KR20230004638A (ko) 화농성 한선염의 치료
WO2019057982A1 (en) TREATMENT OF ATOPIC DERMATITIS
JP2022530063A (ja) 抗体製剤
TW202120546A (zh) 使用介白素-17（il-17）拮抗劑治療狼瘡性腎炎之方法
CN115515978A (zh) 用于治疗呼吸系统疾病的pan-elr+cxc趋化因子抗体
KR20250029297A (ko) 화농성 한선염 치료를 위한 범-elr+ cxc 케모카인 항체
Thomas et al. Individual drugs in rheumatology and the risk of infection
JP2023504679A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して扁平苔癬を治療する方法
CA3187136A1 (en) Methods of treating thyroid eye disease and graves' orbitopahy using interleukin-17 (il-17) antagonists